ES2094653T3 - Derivados de indol como antagonistas de tipo 5-ht1 para uso en la migraña. - Google Patents

Derivados de indol como antagonistas de tipo 5-ht1 para uso en la migraña.

Info

Publication number
ES2094653T3
ES2094653T3 ES94913573T ES94913573T ES2094653T3 ES 2094653 T3 ES2094653 T3 ES 2094653T3 ES 94913573 T ES94913573 T ES 94913573T ES 94913573 T ES94913573 T ES 94913573T ES 2094653 T3 ES2094653 T3 ES 2094653T3
Authority
ES
Spain
Prior art keywords
sub
sup
alkyl
alkylene
cyclloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94913573T
Other languages
English (en)
Inventor
Martin James Wythes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Research and Development Co NV SA
Original Assignee
Pfizer Research and Development Co NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939308360A external-priority patent/GB9308360D0/en
Priority claimed from GB939324433A external-priority patent/GB9324433D0/en
Application filed by Pfizer Research and Development Co NV SA filed Critical Pfizer Research and Development Co NV SA
Application granted granted Critical
Publication of ES2094653T3 publication Critical patent/ES2094653T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LOS COMPUESTOS DE LA FORMULA (I), LAS SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS Y LOS SOLVATOS FARMACEUTICAMENTE ACEPTABLES (INCLUIDOS LOS HIDRATOS) DE CUALQUIER ESPECIE, EN LA QUE R{SUP,1} ES (A); (B); (C); (D); O CH{SUB,2}CH{SUB,2}NR{SUP,3}R{SUP,4} (E); R{SUP,2} ES R{SUP,5}R{SUP,6}C(OH)A O R{SUP,7}COA; R{SUP,3} ES H, ALQUILO C{SUB,1}-C{SUB,6}, ALQUILENO SUSTITUIDO, CICLOALQUILO C{SUB,3}C{SUB,7} OPCIONALMENTE SUSTITUIDO POR HO, ALQUENILO C{SUB,3}C{SUB,6} OPCIONALMENTE SUSTITUIDO POR ARILO, CICLOALQUENILO C{SUB,5}-C{SUB,7} O ALQUINILO C{SUB,3}-C{SUB,6}; R{SUP,4} ES H O ALQUILO C{SUB,1}-C{SUB,6}; R{SUP,5} Y R{SUP,6} SE SELECCIONAN CADA UNO, INDEPENDIENTEMENTE, DEL H, ALQUILO C{SUB,1}-C{SUB,6}, PERFLUORALQUILO C{SUB,1}-C{SUB,4} Y CICLOALQUILO C{SUB,3}C{SUB,7}, O JUNTO CON EL ATOMO DE CARBONO AL QUE SE ENCUENTRAN ENLAZADOS, FORMAN UN ANILLO HETEROCICLICO CARBOCICLICO U OPCIONAL DE 3 A 7 ELEMENTOS; R{SUP,7} ES ALQUILO C{SUB,1}-C{SUB,6}, ALQUILENO SUSTITUIDO, CICLOALQUILO C{SUB,3}-C{SUB,7} O ARILO; A ES UN ENLACE DIRECTO ALQUILENO C{SUB,1}-C{SUB,6} OPCIONALMENTE RAMIFICADO CON UN ALQUILO C{SUB,1}-C{SUB,4} O ALQUENILENO C{SUB,2}-C{SUB,6}; Y K ES 0, 1 O 2; SON AGONISTAS TIPO 5HT{SUB,1} SELECTIVOS UTILES PARA EL TRATAMIENTO DE LA MIGRAINA, DOLOR DE CABEZA LOCALIZADO, HEMICRANIA PAROXISMAL CRONICA Y DOLOR DE CABEZA ASOCIADOS A TRASTORNOS VASCULARES.
ES94913573T 1993-04-22 1994-04-11 Derivados de indol como antagonistas de tipo 5-ht1 para uso en la migraña. Expired - Lifetime ES2094653T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB939308360A GB9308360D0 (en) 1993-04-22 1993-04-22 Indoles
GB939324433A GB9324433D0 (en) 1993-11-27 1993-11-27 Indoles

Publications (1)

Publication Number Publication Date
ES2094653T3 true ES2094653T3 (es) 1997-01-16

Family

ID=26302791

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94913573T Expired - Lifetime ES2094653T3 (es) 1993-04-22 1994-04-11 Derivados de indol como antagonistas de tipo 5-ht1 para uso en la migraña.

Country Status (21)

Country Link
US (1) US5607960A (es)
EP (1) EP0695301B1 (es)
JP (1) JP2802169B2 (es)
KR (1) KR960701865A (es)
CN (1) CN1121348A (es)
AT (1) ATE144773T1 (es)
AU (1) AU6567094A (es)
BR (1) BR9406481A (es)
CA (1) CA2157397C (es)
CZ (1) CZ274595A3 (es)
DE (1) DE69400824T2 (es)
DK (1) DK0695301T3 (es)
ES (1) ES2094653T3 (es)
FI (1) FI954944A0 (es)
GR (1) GR3021804T3 (es)
HU (1) HUT73807A (es)
IL (1) IL109337A0 (es)
NO (1) NO954168D0 (es)
NZ (1) NZ265269A (es)
PL (1) PL311204A1 (es)
WO (1) WO1994024127A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5559246A (en) * 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
US5607951A (en) * 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
CA2169179C (en) * 1993-08-31 2000-02-29 John E. Macor 5-arylindole derivatives
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
GB9420503D0 (en) * 1994-10-11 1994-11-23 Pfizer Ltd Therapeutic agents
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
AU702322B2 (en) * 1995-03-20 1999-02-18 Eli Lilly And Company 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists
US6586458B1 (en) 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US5872145A (en) * 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
AU4074897A (en) * 1996-09-18 1998-04-14 Eli Lilly And Company A method for the prevention of migraine
ES2208955T3 (es) * 1996-11-26 2004-06-16 Nps Allelix Corp. Compuestos 5-ciclo-indolicos como ligandos del receptor 5-ht1d.
US5998462A (en) * 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
US5856510A (en) * 1996-12-16 1999-01-05 Allelix Biopharmaceuticals Inc. 5-alkenyl and 5-alkynyl indole compounds
GB9705035D0 (en) * 1997-03-11 1997-04-30 Pharmacia & Upjohn Spa Indolyl-pyrrolydenemethylpyrrole derivatives and process for their preparation
EP0875513A1 (en) * 1997-04-14 1998-11-04 Eli Lilly And Company Substituted heteroaromatic 5-HT 1F agonists
JP2001512727A (ja) 1997-08-09 2001-08-28 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ−１受容体のリガンドとしてのニ環式化合物
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6310066B1 (en) 1998-04-29 2001-10-30 American Home Products Corp. Antipsychotic indolyl derivatives
US6204274B1 (en) 1998-04-29 2001-03-20 American Home Products Corporation Indolyl derivatives as serotonergic agents
US6066637A (en) * 1998-06-19 2000-05-23 American Home Products Corporation Indolyl derivatives as serotonergic agents
WO2000000490A2 (en) * 1998-06-26 2000-01-06 Eli Lilly And Company 5-ht1f agonists
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
HUP0302820A3 (en) * 2000-07-21 2006-04-28 Lundbeck & Co As H Indole derivatives useful for the treatment of cns disorders and pharmaceutical compositions containing them
US6489512B1 (en) * 2002-06-21 2002-12-03 Rhodia Chirex Inc. Method for making aryl hydrazines and substituted indoles
BR0317126A (pt) * 2002-12-10 2005-10-25 Merck Patent Gmbh Derivados de indol e o uso dos mesmos como ligantes de 5-ht
CN1729174B (zh) * 2002-12-20 2015-10-21 西巴特殊化学品控股有限公司 胺的合成以及用于合成胺的中间体
ES2380827T3 (es) * 2002-12-26 2012-05-18 Pozen, Inc. Formas de dosificación con múltiples capas que contienen naproxeno y triptanes
AU2004247076A1 (en) * 2003-06-06 2004-12-23 Glaxo Group Limited Composition comprising triptans and NSAIDs
US20050245540A1 (en) * 2003-12-09 2005-11-03 Fujisawa Pharmaceutical Co., Ltd. New methods
WO2005066157A1 (en) * 2004-01-02 2005-07-21 Suven Life Sciences 3-(pyrolidin-3-l) indoles as 5-ht6 receptor modulators
GB0807772D0 (en) * 2008-04-29 2008-06-04 Lectus Therapeutics Ltd Calcium ion modulators and uses thereof
FR2953720B1 (fr) * 2009-12-11 2012-05-11 Oreal Utilisation de derives de benzyloxy-ethylamines comme conservateur,
CN104557957B (zh) * 2013-10-09 2017-04-19 华东师范大学 螺‑氧化吲哚环氧乙烷衍生物的合成方法
CN115380028A (zh) * 2020-02-04 2022-11-22 明德赛特制药公司 用于治疗cns病症的作为血清素能致幻剂的3-吡咯烷-吲哚衍生物
AU2024298630A1 (en) * 2023-07-24 2026-02-05 Innovstone Therapeutics Limited 5-ht2a receptor agonist, and preparation method therefor and use thereof
WO2025104491A1 (en) 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8530507D0 (en) * 1985-12-11 1986-01-22 Glaxo Group Plc Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
CA2091562C (en) * 1990-10-15 2001-03-27 John Eugene Macor Indole derivatives useful in psychotherapeutics

Also Published As

Publication number Publication date
JP2802169B2 (ja) 1998-09-24
GR3021804T3 (en) 1997-02-28
NZ265269A (en) 1996-09-25
EP0695301A1 (en) 1996-02-07
BR9406481A (pt) 1996-01-09
FI954944A7 (fi) 1995-10-17
EP0695301B1 (en) 1996-10-30
PL311204A1 (en) 1996-02-05
DK0695301T3 (da) 1996-12-09
FI954944A0 (fi) 1995-10-17
IL109337A0 (en) 1994-07-31
NO954168L (no) 1995-10-19
CN1121348A (zh) 1996-04-24
HUT73807A (en) 1996-09-30
KR960701865A (ko) 1996-03-28
CA2157397A1 (en) 1994-10-27
DE69400824D1 (de) 1996-12-05
NO954168D0 (no) 1995-10-19
WO1994024127A1 (en) 1994-10-27
JPH08507083A (ja) 1996-07-30
CZ274595A3 (en) 1996-03-13
US5607960A (en) 1997-03-04
HU9501920D0 (en) 1995-09-28
DE69400824T2 (de) 1997-03-13
CA2157397C (en) 1999-07-06
AU6567094A (en) 1994-11-08
ATE144773T1 (de) 1996-11-15

Similar Documents

Publication Publication Date Title
ES2149215T3 (es) Bencilaminoquinuclidinas sustituidas como antagonistas de la sustancia p.
ES2113368T3 (es) Antagonistas de serotonina.
ES2058292T3 (es) Derivados de indol.
ES2046202T3 (es) Un procedimiento para preparar un analogo de distamicina a.
CO4700455A1 (es) Derivados tetraciclicos y proceso para su preparacion
ES2116583T3 (es) Compuestos azaciclicos, composiciones que los contienen y su uso como antagonistas de taquicininas.
ATE380818T1 (de) Piperazine-substituierte aryl-benzodiazepinen und ihre verwendung als dopaminrezeptor-antagonisten zur behandlung von psychose
AR119657A1 (es) Compuestos de pirimidina y composiciones farmacéuticas para prevenir o tratar cánceres que incluyen los mismos
ES2137562T3 (es) Derivados hidrosolubles de 3-ariliden-2-oxindol utiles como inhibidores de la kinasa de tirosina.
ES2114952T3 (es) Agentes antianginales derivados de quinazolinona.
NO954168L (no) Indolderivater som 5-HT1-lignende agonister for anvendelse mot migrene
AR055878A1 (es) Derivados de ciclopropanocarboxamida
ES2091299T3 (es) Compuestos azaesteroides para el tratamiento de la hipertrofia prostatica, su preparacion y uso.
ES2062395T3 (es) Nuevos compuestos de bencimidazol y su uso.
AR009413A1 (es) Un compuesto, el cual es un derivado de distamicina benzoheterociclico, su utilizacion, un procedimiento para producirlo y una composicionfarmaceutica que lo comprende
CO5680412A2 (es) Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino
BG96180A (bg) Нови антихистаминови средства,производни на бензимидазолите
ES2180664T3 (es) Derivados de aril- y heteroarilsulfonamida, obtencion y uso de los mismos en calidad de antagonistas de endotelina.
UY24482A1 (es) Quinoxalinadionas
PE20000134A1 (es) Arilpiperazinas que tienen actividad sobre el receptor 1a de la serotonina
UY24429A1 (es) Acetidinas
ES2045126T3 (es) Agentes terapeuticos.
CO5040004A1 (es) 2-4-diamino-1,3,5-triazinas, su preparacion y empleo como herbicidas y fitorreguladores
ES2108595B1 (es) Derivados de la 3(2h)-piridacinona y procedimiento para su preparacion.
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 695301

Country of ref document: ES